-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the 21st, China Pharmaceuticals announced that its subsidiary, Keyi Pharmaceuticals, obtained two "Approval Notices for Supplementary Drug Application for Ganciclovir for Injection" approved and issued by the State Food and Drug Administration.
Ganciclovir is a nucleoside antiviral drug that has a broad-spectrum and highly effective inhibitory effect on herpes virus, can treat cytomegalovirus infection, and has a strong effect on hepatitis B virus and adenovirus
As of the disclosure date of this announcement, the drug research and development expenses have invested approximately RMB 7,281,900 (unaudited)